These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 15567452)

  • 21. Differentiation of the low-molecular-weight heparins.
    Racine E
    Pharmacotherapy; 2001 Jun; 21(6 Pt 2):62S-70S; discussion 71S-72S. PubMed ID: 11401195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study.
    Mahé I; Aghassarian M; Drouet L; Bal Dit-Sollier C; Lacut K; Heilmann JJ; Mottier D; Bergmann JF
    Thromb Haemost; 2007 Apr; 97(4):581-6. PubMed ID: 17393021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
    Polkinghorne KR; McMahon LP; Becker GJ
    Am J Kidney Dis; 2002 Nov; 40(5):990-5. PubMed ID: 12407644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases.
    Agnelli G; Iorio A; Renga C; Boschetti E; Nenci GG; Ofosu FA; Hirsh J
    Circulation; 1995 Nov; 92(10):2819-24. PubMed ID: 7586247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of thrombotic and cardiovascular disorders in the new millenium.
    Fareed J; Hoppensteadt DA; Bick RL
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
    Collignon F; Frydman A; Caplain H; Ozoux ML; Le Roux Y; Bouthier J; Thébault JJ
    Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
    Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
    Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications.
    Florian-Kujawski M; Hoppensteadt D; Maddineni J; Ziegler H; Fareed J
    Int Angiol; 2004 Dec; 23(4):346-54. PubMed ID: 15767980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy.
    Ensom MH; Stephenson MD
    J Soc Gynecol Investig; 2004 Sep; 11(6):377-83. PubMed ID: 15350250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy.
    Hansen JB; Sandset PM
    Thromb Res; 1998 Aug; 91(4):177-81. PubMed ID: 9736420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
    Wells PS; Anderson DR; Rodger MA; Forgie MA; Florack P; Touchie D; Morrow B; Gray L; O'Rourke K; Wells G; Kovacs J; Kovacs MJ
    Arch Intern Med; 2005 Apr; 165(7):733-8. PubMed ID: 15824291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa.
    Lin P; Sinha U; Betz A
    Biochim Biophys Acta; 2001 Apr; 1526(1):105-13. PubMed ID: 11287128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates.
    Jeske W; Fareed J
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():41-7. PubMed ID: 15085465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of low molecular weight heparins.
    Bara L; Samama M
    Acta Chir Scand Suppl; 1990; 556():57-61. PubMed ID: 1963018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model.
    Ao PY; Hawthorne WJ; Coombs R; Fletcher JP
    Int Angiol; 1999 Jun; 18(2):131-9. PubMed ID: 10424369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of low-molecular-weight heparin and unfractionated heparin during elective aortobifemoral bypass grafting.
    Kroneman H; Eikelboom BC; Knot EA; de Smit P; Groenland TH; de Maat MP; Van Urk H
    J Vasc Surg; 1991 Aug; 14(2):208-14. PubMed ID: 1650406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
    Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiproliferative effects of low molecular weight heparin.
    Fletcher JP; Ao PY; Hawthorne WJ
    ANZ J Surg; 2004 Sep; 74(9):793-6. PubMed ID: 15379813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.